Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients
09. September 2024 11:45 ET
|
Boehringer Ingelheim
Beamion LUNG-1, Phase Ib met its primary endpoint, demonstrating a meaningful objective response rate (ORR) of 66.7%, as assessed by blinded independent central review (BICR)1Preliminary activity in...
Boehringer Ingelheim to unveil groundbreaking oncology research at WCLC, demonstrating strength of portfolio
27. August 2024 03:05 ET
|
Boehringer Ingelheim
Data from the phase Ib Beamion LUNG-1 trial selected for late-breaking oral presentation in the Presidential Symposium at WCLC on Monday, September 9. The U.S. FDA and China's CDE have granted...
MAIA Biotechnology Completes Enrollment in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer
22. Februar 2024 10:30 ET
|
MAIA Biotechnology, Inc.
Topline data expected in second half of 2024THIO-101 will be the first completed clinical study of a telomere targeting agent in the field of cancer drug discovery and treatment CHICAGO, IL, Feb. ...
Lung Cancer Therapy Market Share Worth $80.49 Billion, Globally, by 2030 - Exclusive Report by The Insight Partners
01. November 2023 06:46 ET
|
The Insight Partners
Pune, India, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Lung cancer now a days is treated by targeted therapy, a type of personalized medicine, is a combination of two or more drugs, designed to directly...
Ocean Biomedical Announces Newly Published Findings Demonstrating Ability to Restore Treatment Sensitivity to AstraZeneca’s Leading Lung Cancer Drug After Resistance Has Formed, and Enhanced Tumor Suppression in EGFR-Mutation Lung Cancers
03. Oktober 2023 08:01 ET
|
Ocean Biomedical, Inc.
Company to Host Cancer R&D Update on October 19, 2023 to Share Latest Details of Multipronged Cancer Program Based on Pioneering Anti-CHI3L1 Discoveries Providence, RI, Oct. 03, 2023 (GLOBE...
Non-Small Cell Lung Cancer Market to Surpass 76.33 Billion by 2030 Drives Due to Rising Incidence of Non-Small Cell Lung Cancer Diagnoses
28. August 2023 09:30 ET
|
SkyQuest Technology Consulting Pvt. Ltd.
Westford, USA, Aug. 28, 2023 (GLOBE NEWSWIRE) -- According to SkyQuest, the trajectory of the non-small cell lung cancer market is poised for advancement, propelled by a noteworthy trend – the...
ImPact Biotech receives FDA Clearance for Padeliporfin VTP Phase 1 Clinical Program in Peripheral Lung Cancer
04. August 2023 10:49 ET
|
ImPact Biotech
Padeliporfin VTP Phase 1 trial in Peripheral Non-Small Cell Lung Cancer to start by end Q4 2023 TEL AVIV, Israel, Aug. 04, 2023 (GLOBE NEWSWIRE) -- ImPact Biotech,...
PD-1 Non-Small Cell Lung Cancer Clinical Trials Pipeline Analysis: 20+ Companies are Working to Improve the Treatment Space | DelveInsight
20. Juni 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, June 20, 2023 (GLOBE NEWSWIRE) -- PD-1 Non-Small Cell Lung Cancer Clinical Trials Pipeline Analysis: 20+ Companies are Working to Improve the Treatment Space | DelveInsight The...
FDA Approves IND Submission Allowing ABVC BioPharma to Proceed With Clinical Study of ABV-1519 for Treatment of Non-Small Cell Lung Cancer
05. Januar 2023 08:30 ET
|
ABVC BioPharma, Inc.
FREMONT, CA, Jan. 05, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
Non-Small Cell Lung Cancer Market Value to reach US$ 20 Billion by 2033, Experiencing 2X Growth across the Coming Decade: Future Market Insights, Inc. Report
29. Dezember 2022 08:30 ET
|
Future Market Insights Global and Consulting Pvt. Ltd.
NEWARK, Del, Dec. 29, 2022 (GLOBE NEWSWIRE) -- A recently published study by FMI expects the global Non-small cell lung cancer market to augment at a 7.2% CAGR from 2023 to 2033. By the end of the...